KING OF PRUSSIA, PA — Aclipse Therapeutics has entered a clinical collaboration with Mayo Clinic to advance a Phase 2 study of M107, a novel small-molecule drug positioned as the first potential disease-modifying treatment for gastroparesis, a chronic condition marked by stomach paralysis and severely delayed gastric emptying.
Under the agreement, Aclipse will provide research support while Mayo Clinic leads the upcoming investigation, known as the LOGAST trial. Enrollment is expected to begin in the first quarter of 2026 and will span three Mayo Clinic campuses in Minnesota, Arizona, and Florida, involving roughly 10 clinical investigators.
Gastroparesis, which disrupts signals between the stomach’s muscles and nerves, has long lacked therapies that address its underlying biology. M107 targets macrophage-driven inflammation — a mechanism increasingly linked to the disease — by shifting harmful pro-inflammatory M1 macrophages toward anti-inflammatory M2 macrophages. Aclipse said this dual action highlights the drug’s potential to modify disease progression rather than simply manage symptoms.
Raymond K. Houck, Aclipse Therapeutics’ chief executive officer, said the collaboration reflects a joint commitment to delivering new options for a patient population with limited treatments. He described M107 as an oral candidate with a favorable safety profile and anti-inflammatory benefits that directly address macrophage dysregulation in gastroparesis.
The trial will be led by Dr. Pankaj Jay Pasricha, chair of internal medicine at Mayo Clinic Arizona, and will evaluate M107 in patients with idiopathic gastroparesis. The study is investigator-initiated and sponsored by Mayo Clinic.
Mayo Clinic noted that it holds a financial interest in the technology referenced in the collaboration and will use any revenue generated to support its not-for-profit mission in patient care, education, and research.
If successful, M107 would represent a rare breakthrough in a field where current therapies focus primarily on symptom management rather than disease modification — a gap that has left many patients with persistent, debilitating gastrointestinal dysfunction.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.